SynthesisThe Cochrane database of systematic reviews2001
D-Penicillamine for preventing retinopathy of prematurity in preterm infants.
Synthesis in The Cochrane database of systematic reviews, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Concordance of effects of medical interventions on hospital admission and readmission rates with effects on mortality.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2013Pooled it
- D-Penicillamine for preventing retinopathy of prematurity in preterm infants.The Cochrane database of systematic reviews · 2013Pooled it
- Treatment of retinopathy of prematurity with topical ketorolac tromethamine: a preliminary study.BMC pediatrics · 2004Trial
- Sigma 1 Receptor Activation Coordinates Metabolic Stress Responses to Protect Retinal Vasculature in Ischemic Retinopathy.Investigative ophthalmology & visual science · 2026Article
- D-Penicillamine: The State of the Art in Humans and in Dogs from a Pharmacological and Regulatory Perspective.Antibiotics (Basel, Switzerland) · 2021Review
- Comment on "New Antioxidant Drugs for Neonatal Brain Injury".Oxidative medicine and cellular longevity · 2015Article
- Retinopathy of prematurity.Lancet (London, England) · 2013Review
- The effects of D-penicillamine on a murine model of oxygen-induced retinopathy.Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus · 2011Article
- [Risk factors and prevention of retinopathy of prematurity].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2008Review
- D-Penicillamine administration and the incidence of retinopathy of prematurity.Journal of perinatology : official journal of the California Perinatal Association · 2007Article
- Oxygen and retinopathy of prematurity.Journal of perinatology : official journal of the California Perinatal Association · 2006Review
- A pilot trial testing the feasibility of administering D-penicillamine to extremely low birth weight neonates.Journal of perinatology : official journal of the California Perinatal Association · 2006Article
Corrections and comments
- Updated by
- Update of
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRetinopathy of prematurity remains a common problem. A low rate of this disorder was unexpectedly observed among infants treated with intravenous d-penicillamine to prevent hyperbilirubinemia. This observation led to the investigation of its use to prevent retinopathy of prematurity.
objectivesTo answer the question: Among very low birth weight infants, what is the effect of prophylactic administration of d-penicillamine on the incidence of acute ROP or severe ROP, and side effects including death? SEARCH STRATEGY: Searches were made of multiple electronic databases, previous reviews including cross references, abstracts, conference/symposia proceedings, and expert informants. The search was updated to November 2000. SELECTION CRITERIA: Randomized or quasi-randomized controlled trials that administered d-penicillamine to infants less than 2000g birth weight within the day following birth were considered relevant to this review. Additional case series were examined for potential side effects. DATA COLLECTION AND ANALYSIS: Data on clinical outcomes were excerpted by 3 reviewers independently, and consensus reached. Data analysis was conducted according to the standards of the Neonatal Cochrane Review Group. MAIN
resultsTwo randomized trials on the effects on ROP were identified. When combined, they showed a significantly lower incidence of acute ROP in the treated infants, relative risk of 0.09, 95% CI [0.01,0.71]. Severe stages of ROP could not be analyzed. There was no effect on death rates, relative risk 0.99 95% CI [0.70,1.39]. No side effects were reported, and follow up at one year revealed no significant differences in spasticity or developmental delay, although there were more rehospitalizations among the controls. In other reports of using d-penicillamine in over 140 infants for hyperbilirubinemia, skin rashes were reported in 2 infants and one had vomiting that may have been related. REVIEWER'S
conclusionsD-penicillamine is unlikely to affect survival, and may reduce the incidence of acute ROP among survivors. Studies to date justify further investigation of this drug in a broader population; careful attention to possible side effects is needed.
Indexed as
Identifiers
11279704What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.